Impact of intravesical onabotulinumtoxinA on sexual function in women with OAB

Neurourol Urodyn. 2017 Aug;36(6):1564-1569. doi: 10.1002/nau.23148. Epub 2016 Oct 4.

Abstract

Aims: Urgency urinary incontinence (UUI), and the symptoms of overactive bladder (OAB) have a negative impact on female sexual function. The aim of this study was to investigate the effect of intravesical onabotulinumtoxinA (Botox) injection on sexual function in women with OAB, using the multi domain Female Sexual Function Index (FSFI) questionnaire.

Methods: Sixty-eight sexually active women with idiopathic OAB with at least one episode of UUI and ≥8 micturitions per 24 h were recruited. Patients completed the FSFI questionnaire before and 12 weeks after treatment with intravesical onabotulinumtoxinA injections. Baseline scores were compared with a control group of age-matched healthy women.

Results: Fifty-six women completed the study. At baseline OAB patients reported decreased quality of sexual function in all domains measured with FSFI, in comparison to healthy women (median 21.8 vs. 26.3, P < 0.001). Over 90% of participants reported clinically relevant improvements in sexual function, with statistically significant changes in mean scores in all six domains.

Conclusions: Intravesical Botox injections provide improvement in sexual function in women with OAB. Neurourol. Urodynam. 9999:XX-XX, 2016. © 2016 Wiley Periodicals, Inc.

Keywords: Botox; onabotulinumtoxinA; overactive bladder; quality of life; sexual function; urgency incontinence.

MeSH terms

  • Administration, Intravesical
  • Adult
  • Botulinum Toxins, Type A / administration & dosage
  • Botulinum Toxins, Type A / therapeutic use*
  • Female
  • Humans
  • Middle Aged
  • Sexual Dysfunction, Physiological / drug therapy*
  • Sexual Dysfunction, Physiological / physiopathology
  • Surveys and Questionnaires
  • Treatment Outcome
  • Urinary Bladder, Overactive / drug therapy*
  • Urinary Bladder, Overactive / physiopathology
  • Urination / drug effects

Substances

  • Botulinum Toxins, Type A